Kadcyla 160 MG vials
Ended Awarded
- Contract number
- SPE2DB25FTA12
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,871
Award facts
- Contract value 100% obligated
- $16,871.44 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $16,871.44 by the Defense Logistics Agency on September 26, 2025. The contract, which carries no set-aside designation, calls for the delivery of Kadcyla 160 mg vials with an ultimate completion date of October 20, 2025. This delivery order is issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499,999,999 vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products and medical supplies.
Kadcyla is a targeted cancer therapy used in oncology treatment, consistent with DMS Pharmaceutical Group's established portfolio of specialty pharmaceutical products distributed to Department of Defense healthcare facilities. The company has demonstrated sustained success in federal pharmaceutical procurement, leveraging its woman-owned small business status to compete effectively across multiple product categories including branded and generic prescription drugs, biologics, and medical consumables. This award reinforces DMS Pharmaceutical Group's critical role as a direct pharmaceutical supplier supporting military health facility operations nationwide.
Quick answers
Who was awarded contract SPE2DB25FTA12?
SPE2DB25FTA12 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 26, 2025.
How much is contract SPE2DB25FTA12 worth?
The government has obligated $16,871 on SPE2DB25FTA12.
Is contract SPE2DB25FTA12 an order under another contract?
Yes. SPE2DB25FTA12 is a delivery order under SPE2DB22D9367, an indefinite delivery contract.
Was contract SPE2DB25FTA12 competed?
The extent of competition for SPE2DB25FTA12 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award